Recruitment and development of talented CRAs
First written in FY2016. 10 of 21 entries say "Advanced", first in FY2017-Q2. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「In addition, for personnel whose foundation is experience in monitoring operations, we are developing talent able to take a comprehensive view of the business by gradually providing work experience in peripheral areas such as medical writing, regulatory affairs, and project management. Through this, we aim to deepen their understanding of clinical trial operations, broaden their expertise, and build a talent pool capable of handling more advanced work.」
A specific development program has been established to gradually expand the experience of personnel such as CRAs from monitoring into medical writing, regulatory affairs, and project management. Collaboration with external medical doctors, the development of a Playbook, and IT training are also described. - FY2025-H1AdvancedAnnual report
「Inquiries have recently been increasing, and we are strengthening our organization by hiring sales personnel in Europe while focusing on expanding orders.」
It was stated that sales personnel were being hired in Europe to strengthen the sales organization and expand orders. No figures, such as the number of hires, are provided. - FY2024Decrease in the number of employees and natural attritionAnnual report
「The 97-person decrease in the number of employees during the fiscal year was mainly due to natural attrition, including voluntary resignations.」
The consolidated workforce decreased by 97, from 759 in the previous fiscal year to 662, with natural attrition, including voluntary resignations, cited as the main cause. - FY2024-Q2RestatedAnnual report
「In South Korea, revenue increased year on year due to steady progress on existing projects, the launch of multiple new projects, and the weaker yen. Profit declined because of front-loaded investment in personnel.」
Front-loaded investment in personnel, including staffing to handle new projects, continued in South Korea and became a factor reducing profit despite higher revenue. - FY2023-Q3Adjusting hiring levels and managing personnel expensesAnnual report
「In Japan, revenue declined, mainly because the timing of clinical trial starts was changed at the sponsors' request during the first half, resulting in a decline for the nine-month period as well. Strict control of personnel expenses and other costs through adjustments to hiring levels absorbed higher costs, including those for enhanced information security, and resulted in higher profit year on year.」
In Japan, the company described a policy of adjusting hiring levels and strictly controlling personnel expenses and other costs. This indicates not only an expansion of personnel recruitment but also adjustments to hiring and expense management in line with project conditions. - FY2023-Q2AdvancedAnnual report
「Revenue in South Korea increased year on year, helped by the acquisition and launch of multiple new projects and the weaker yen. On the profit side, the impact of an operating loss in the first quarter, caused by front-loaded personnel expenses from increased staffing to handle new projects, was substantial; although profit increased year on year in the second quarter, profit declined on a cumulative basis.」
In South Korea, multiple new projects were acquired and launched, and the resulting increase in staffing led to an actual increase in front-loaded personnel expenses. - FY2023-Q1AdvancedAnnual report
「However, operating profit fell into the red because temporary underutilization of personnel, resulting from delays in the start of large-scale global clinical trials in the United States and Europe after sponsors revised their clinical trial plans, among other factors, coincided with increased staffing to handle the launch of 10 or more new projects scheduled from the second quarter onward and additional workload in the United States, Europe, and South Korea.」
It was stated that staffing was being increased in the United States, Europe, and South Korea to handle 10 or more new projects scheduled from the second quarter onward and additional workload. - FY2021Description of a decrease in the number of employees due to natural attritionAnnual report
「The 3-person decrease in the number of employees during the fiscal year was mainly due to natural attrition, including voluntary resignations.」
While continuing to secure and develop personnel, the company reported natural attrition, including voluntary resignations, in its workforce during the fiscal year. The consolidated workforce was 845. - FY2020AdvancedAnnual report
「The 19-person increase in the number of employees during the fiscal year was mainly attributable to regular and mid-year hiring associated with business expansion.」
The consolidated workforce increased by 19 over the full year through hiring associated with business expansion. - FY2020-Q1RestatedAnnual report
「Cost of sales for the three months ended 30 June was ¥1,938 million, up 1.8% year on year, mainly as a result of higher personnel expenses due to front-loaded investment in personnel and promotions and salary increases, and higher rent, although the effects of LAA's cost-cutting measures had begun to emerge.」
Higher personnel expenses due to front-loaded investment in personnel, promotions, and salary increases continued. No specific progress, such as the number of new hires, is provided. - FY2019AdvancedAnnual report
「The 151-person increase in the number of employees during the fiscal year was mainly attributable to regular and mid-year hiring associated with business expansion, as well as the inclusion of Accelovance, Inc. and its subsidiaries, acquired by LINICAL USA, INC., in the scope of consolidation. Accelovance, Inc. has since changed its corporate name to Linical Accelovance America, Inc.」
The consolidated workforce increased by 151 over the full year. In addition to hiring associated with business expansion, the inclusion of Accelovance and its subsidiaries in the scope of consolidation is specifically identified as contributing to the increase in personnel. - FY2019-Q3RestatedAnnual report
「Cost of sales for the nine months ended 31 December was ¥5,566 million, up 35.7% year on year, mainly as a result of increasing staffing in preparation for growth in the number of outsourced clinical trial projects.」
The increase in staffing in preparation for growth in the number of outsourced clinical trial projects, and the resulting increase in cost of sales including personnel expenses, continue to be described. No milestones, such as the number of new hires, are provided. - FY2019-Q1RestatedAnnual report
「Cost of sales for the three months ended 30 June was ¥1,903 million, up 31.8% year on year, mainly as a result of higher personnel expenses due to front-loaded investment in personnel and promotions and salary increases, among other factors.」
Front-loaded investment in personnel continued to appear as an increase in cost of sales including personnel expenses. No specific progress, such as the number of new hires, is provided. - FY2018AdvancedAnnual report
「The 73-person increase in the number of employees during the fiscal year was mainly attributable to regular and mid-year hiring associated with business expansion.」
The number of employees increased by 73 over the full year in response to business expansion, with hiring-related personnel recruitment reflected in the increase in headcount. - FY2018-Q3AdvancedAnnual report
「Profit declined because personnel expenses, rent, and other costs increased as planned, following the hiring of personnel and relocation of the Tokyo office at the beginning of the fiscal year to increase floor space and staffing in line with the order plan, which included the projects described above that had already been awarded in the previous fiscal year but had not started.」
It is stated that the Tokyo office was relocated at the beginning of the fiscal year to hire personnel and increase floor space in response to the order plan. - FY2018-Q2RestatedAnnual report
「Cost of sales for the six months ended 30 September was ¥2,629 million, up 21.8% year on year, mainly as a result of increasing staffing in preparation for growth in the number of outsourced clinical trial projects.」
The increase in staffing in preparation for growth in the number of outsourced clinical trial projects, and the resulting increase in cost of sales including personnel expenses, continue to be described. No milestones, such as the number of new hires, are provided. - FY2018-Q1RestatedAnnual report
「Cost of sales for the three months ended 30 June was ¥1,444 million, up 19.8% year on year, mainly as a result of higher personnel expenses arising from front-loaded investment in personnel and costs associated with relocating the Tokyo office, among other factors.」
Front-loaded investment in personnel continued to appear as higher personnel expenses. No specific milestones, such as the number of new hires, are described. - FY2017AdvancedAnnual report
「The 70-person increase in the number of employees during the fiscal year was mainly attributable to regular and mid-year hiring associated with business expansion.」
The number of employees increased by 70 over the full year in response to business expansion, confirming that efforts to secure personnel, including mid-career hires, new graduates, and inexperienced candidates, resulted in an increase in headcount. - FY2017-Q3RestatedAnnual report
「Cost of sales for the nine months ended 31 December was ¥3,402 million, up 9.4% year on year, mainly as a result of increasing staffing in preparation for growth in the number of outsourced clinical trial projects.」
The increase in staffing and related expenses in preparation for growth in the number of outsourced clinical trial projects continues to be described. - FY2017-Q2AdvancedAnnual report
「Cost of sales for the six months ended 30 September was ¥2,159 million, up 9.0% year on year, mainly as a result of increasing staffing in preparation for growth in the number of outsourced clinical trial projects.」
Staffing was increased in preparation for growth in the number of outsourced clinical trial projects, and investment in personnel has specifically appeared as an increase in expenses. - FY2016First statedAnnual report
「To secure personnel, we will actively recruit excellent mid-career candidates who can contribute immediately, while identifying and recruiting new graduates and inexperienced candidates with the aptitude to become CRAs.」
In addition to mid-career recruitment, the company regards recruiting and developing new graduates and inexperienced candidates as prerequisites for business expansion.